U.S. federal prosecutors are investigating six pharmaceutical companies for potential criminal charges in connection with shipping large quantities of opioid painkillers that contributed to a health-care crisis, according to regulatory filings.
Five companies have received subpoenas from the U.S. Attorney’s office in the Eastern District of New York as part of the investigation: drugmakers Teva Pharmaceutical Industries Ltd., Mallinckrodt PLC, Johnson & Johnson and Amneal Pharmaceuticals Inc., and distributor McKesson Corp., regulatory filings showed.
The Wall Street Journal first reported the investigation on Tuesday. The newspaper said the probe was in the early stages and prosecutors were expected to subpoena other companies in the coming months, citing a source.
A spokesman for the U.S. Attorney’s office for the Eastern District of New York declined to comment.
The WSJ also said distributor AmerisourceBergen Corp. had received a subpoena as part of the investigation. The company said in regulatory filings that it has received subpoenas from multiple U.S. attorneys including the Eastern District of New York, but unlike the other companies, AmerisourceBergen did not specify the nature of the probe.
Shares of AmerisourceBergen, Amneal, Teva, Mallinckrodt and McKesson ended down 3 per cent to 9 per cent, while J&J shares were down marginally after the report. J&J’s disclosure of the investigation was reported by Reuters in October.
Teva said it was confident in its monitoring practices, which it said were designed to ensure medicines were delivered appropriately.
McKesson referred to recent regulatory filings while the other companies did not immediately respond to requests for comment.
Opioid manufacturers, distributors and pharmacy chains have been defending themselves against thousands of lawsuits by state attorneys-general, local governments and class actions accusing them of fuelling an addiction crisis.
Opioids have contributed to more than 400,000 deaths since 1997.
Some of the companies’ filings described the subpoenas as part of an industry-wide probe into anti-diversion policies and distribution of opioid medications under the Controlled Substances Act.
Several companies said they received grand jury subpoenas, indicating a criminal investigation.
The CSA requires companies to report orders of controlled substances such as opioids that are unusually large or unusually frequent, or that substantially deviate from norm.
In Canada, several provincial governments have joined a class-action lawsuit to recoup the costs of fighting the opioid crisis from opioid manufacturers and distributors, including pharmacies. The B.C. government’s proposed class-action lawsuit was filed a year ago against dozens of pharmaceutical companies. Newfoundland and Labrador, Ontario and Alberta have already announced their support. Saskatchewan joined them on Monday.
The lawsuit seeks costs from manufacturers and distributors dating back to 1996, when the pain drug OxyContin was introduced in the Canadian market. The suit alleges the companies falsely marketed opioids as less addictive than other pain drugs and helped start an overdose crisis that has killed more than 12,800 Canadians since January, 2016.
In July, federal prosecutors charged an Ohio drug distributor, Miami-Luken Inc, for shipping millions of opioid pills to rural Appalachia, ground zero for the epidemic.
The company shipped 3.7 million hydrocodone pills from 2008 to 2011 to a pharmacy in Kermit, W.Va., a town of just 400 people, prosecutors said.
In 2016, distributor Cardinal Health Inc. agreed to pay US$44-million to resolve allegations it violated the CSA by filling unusually large orders of oxycodone without reporting them.
Teva, Mallinckrodt and J&J also recently disclosed they had received subpoenas from the New York State Department of Financial Services. J&J said it was part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.
With a report from The Canadian Press
This content appears as provided to The Globe by the originating wire service. It has not been edited by Globe staff.